372 related articles for article (PubMed ID: 17347152)
21. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies.
Ramani VC; Purushothaman A; Stewart MD; Thompson CA; Vlodavsky I; Au JL; Sanderson RD
FEBS J; 2013 May; 280(10):2294-306. PubMed ID: 23374281
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior.
Bandari SK; Purushothaman A; Ramani VC; Brinkley GJ; Chandrashekar DS; Varambally S; Mobley JA; Zhang Y; Brown EE; Vlodavsky I; Sanderson RD
Matrix Biol; 2018 Jan; 65():104-118. PubMed ID: 28888912
[TBL] [Abstract][Full Text] [Related]
23. Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis.
Sanderson RD; Yang Y; Suva LJ; Kelly T
Matrix Biol; 2004 Oct; 23(6):341-52. PubMed ID: 15533755
[TBL] [Abstract][Full Text] [Related]
24. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
[TBL] [Abstract][Full Text] [Related]
25. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse.
Ramani VC; Sanderson RD
Matrix Biol; 2014 Apr; 35():215-22. PubMed ID: 24145151
[TBL] [Abstract][Full Text] [Related]
27. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases.
Kelly T; Suva LJ; Huang Y; Macleod V; Miao HQ; Walker RC; Sanderson RD
Cancer Res; 2005 Jul; 65(13):5778-84. PubMed ID: 15994953
[TBL] [Abstract][Full Text] [Related]
28. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis.
Edovitsky E; Elkin M; Zcharia E; Peretz T; Vlodavsky I
J Natl Cancer Inst; 2004 Aug; 96(16):1219-30. PubMed ID: 15316057
[TBL] [Abstract][Full Text] [Related]
29. Mammalian heparanase as mediator of tumor metastasis and angiogenesis.
Vlodavsky I; Elkin M; Pappo O; Aingorn H; Atzmon R; Ishai-Michaeli R; Aviv A; Pecker I; Friedmann Y
Isr Med Assoc J; 2000 Jul; 2 Suppl():37-45. PubMed ID: 10909416
[TBL] [Abstract][Full Text] [Related]
30. Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas.
Mikami S; Ohashi K; Usui Y; Nemoto T; Katsube K; Yanagishita M; Nakajima M; Nakamura K; Koike M
Jpn J Cancer Res; 2001 Oct; 92(10):1062-73. PubMed ID: 11676857
[TBL] [Abstract][Full Text] [Related]
31. Heparanase promotes myeloma stemness and in vivo tumorigenesis.
Tripathi K; Ramani VC; Bandari SK; Amin R; Brown EE; Ritchie JP; Stewart MD; Sanderson RD
Matrix Biol; 2020 Jun; 88():53-68. PubMed ID: 31812535
[TBL] [Abstract][Full Text] [Related]
32. Significance of host heparanase in promoting tumor growth and metastasis.
Zhang GL; Gutter-Kapon L; Ilan N; Batool T; Singh K; Digre A; Luo Z; Sandler S; Shaked Y; Sanderson RD; Wang XM; Li JP; Vlodavsky I
Matrix Biol; 2020 Nov; 93():25-42. PubMed ID: 32534153
[TBL] [Abstract][Full Text] [Related]
33. Nuclear Heparanase Regulates Chromatin Remodeling, Gene Expression and PTEN Tumor Suppressor Function.
Amin R; Tripathi K; Sanderson RD
Cells; 2020 Sep; 9(9):. PubMed ID: 32899927
[TBL] [Abstract][Full Text] [Related]
34. Specific genes involved in synthesis and editing of heparan sulfate proteoglycans show altered expression patterns in breast cancer.
Fernández-Vega I; García O; Crespo A; Castañón S; Menéndez P; Astudillo A; Quirós LM
BMC Cancer; 2013 Jan; 13():24. PubMed ID: 23327652
[TBL] [Abstract][Full Text] [Related]
35. Involvement of Syndecan-1 and Heparanase in Cancer and Inflammation.
Teixeira FCOB; Götte M
Adv Exp Med Biol; 2020; 1221():97-135. PubMed ID: 32274708
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of heparanase inhibitors in cancer therapy.
Heyman B; Yang Y
Exp Hematol; 2016 Nov; 44(11):1002-1012. PubMed ID: 27576132
[TBL] [Abstract][Full Text] [Related]
37. Properties and function of heparanase in cancer metastasis and angiogenesis.
Vlodavsky I; Goldshmidt O
Haemostasis; 2001; 31 Suppl 1():60-3. PubMed ID: 11990483
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of extracellular superoxide dismutase attenuates heparanase expression and inhibits breast carcinoma cell growth and invasion.
Teoh ML; Fitzgerald MP; Oberley LW; Domann FE
Cancer Res; 2009 Aug; 69(15):6355-63. PubMed ID: 19602586
[TBL] [Abstract][Full Text] [Related]
39. Heparan sulfate mediates trastuzumab effect in breast cancer cells.
Suarez ER; Paredes-Gamero EJ; Del Giglio A; Tersariol IL; Nader HB; Pinhal MA
BMC Cancer; 2013 Oct; 13():444. PubMed ID: 24083474
[TBL] [Abstract][Full Text] [Related]
40. Heparanase promotes the spontaneous metastasis of myeloma cells to bone.
Yang Y; Macleod V; Bendre M; Huang Y; Theus AM; Miao HQ; Kussie P; Yaccoby S; Epstein J; Suva LJ; Kelly T; Sanderson RD
Blood; 2005 Feb; 105(3):1303-9. PubMed ID: 15471949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]